Frohmüller H, Theiss M, Wirth M, Hofmockel G
Urologische Klinik und Poliklinik, Universität Würzburg.
Urologe A. 1995 May;34(3):225-30.
From July 1969 to May 1994, radical prostatectomy was performed in 630 patients with clinically localized prostate cancer at the Department of Urology, University of Würzburg Medical School. These included 74 patients subsequently followed up for 15 years or more 15 years (15-23 years, mean 17.5 years), who were the subjects of the present study. Of these 74 patients 59 had pT2 tumors and 10 had pT3 tumors according to the staging criteria of the 1992 edition of the UICC TNM classification. The remaining 5 patients had microscopic lymph node metastases detected at staging pelvic lymphadenectomy (stage pT2-3pN1-2). Patients with lymph node involvement were treated by immediate orchiectomy. All other patients received no further treatment until progression occurred. The overall 15-year survival rate actually observed the 74 patients was 50% (37/74) and the disease-free survival rate was 43.2% (32/74 pts). Stage-related overall and disease-free survival rates were found to be 54.2% and 49.1%, respectively, for patients with pT2 tumors, 40% and 30% for those with pT3 tumors, and 20% and 0 for patients with lymph node metastases. Progression (either local recurrence or distant metastatic spread) was noted in 22 of the 74 patients (29.7%) within the 15-year period following radical prostatectomy. Mean time to progression was 7.9 years (3 months to 17 years). Within the follow-up period, 17 patients (23%) died of prostate cancer. These actual 15-year follow-up data show radical prostatectomy to be the most effective means of achieving long-term disease-free survival, if not cure, in patients with clinically localized prostate cancer.
1969年7月至1994年5月,维尔茨堡大学医学院泌尿外科对630例临床局限性前列腺癌患者实施了根治性前列腺切除术。其中74例患者随后接受了15年或更长时间(15 - 23年,平均17.5年)的随访,他们是本研究的对象。根据1992年版UICC TNM分类的分期标准,这74例患者中,59例为pT2肿瘤,10例为pT3肿瘤。其余5例患者在分期盆腔淋巴结清扫术中检测到微小淋巴结转移(pT2 - 3pN1 - 2期)。有淋巴结受累的患者立即接受了睾丸切除术。所有其他患者在疾病进展前未接受进一步治疗。实际观察到的这74例患者的15年总生存率为50%(37/74),无病生存率为43.2%(32/74例)。pT2肿瘤患者的分期相关总生存率和无病生存率分别为54.2%和49.1%,pT3肿瘤患者分别为40%和30%,有淋巴结转移的患者分别为20%和0。在根治性前列腺切除术后的15年期间,74例患者中有22例(29.7%)出现疾病进展(局部复发或远处转移)。进展的平均时间为7.9年(3个月至17年)。在随访期间,17例患者(23%)死于前列腺癌。这些实际的15年随访数据表明,对于临床局限性前列腺癌患者,根治性前列腺切除术是实现长期无病生存(即使不能治愈)的最有效方法。